HLA-E and acute lymphoblastic leukemia: Ex vivo experiments have shown that adaptive NK cells enriched in HLA-E ligands have enhanced alloreactivity to HLA-mismatched targets and even serve as a specific and efficient killer of allogeneic pediatric T- and precursor B-cell acute lymphoblastic leukemia (ALL) blasts (89).